


Meningococcal Vaccines for Adolescents & Young Adults: Routine Risk¹




Routine MenACWY^{2,3} for 11-18 years

2 Doses



Shared Clinical Decision-Making MenB² for 16-23 years

2 Doses

Preferred age is 16-18 years



Pentavalent Vaccine (MenABCWY)² Suggested Dosing for 11-23 years

3 Doses


Notes:

1. For **high-risk populations** (increased exposure to meningococcal disease, HIV infection, complement deficiencies or asplenia), ([EZIZ.org/assets/docs/IMM-1218.pdf](#)) ([CDC.gov/mmwr/volumes/69/rr/rr6909a1.htm#T3_down](#))
2. MenACWY and MenB vaccines each protect against different serogroups. They may be given at the same visit. If a patient is receiving MenACWY and MenB vaccines at the same visit, **MenABCWY** may be given instead.
3. MenACWY (MCV4) vaccines protect against serogroups A, C, W-135, and Y.
4. One dose of MenACWY is also recommended for previously unvaccinated or incompletely vaccinated first-year college students living in residence halls and military recruits and may be administered to persons aged 19-21 yrs. who have not received a dose after their 16th birthday.
5. A two-dose series is recommended for persons who are not at increased risk for meningococcal disease. A three-dose (0, 1-2, and 6 months) series is recommended for **persons at increased risk, including during outbreaks of serogroup B disease** ([EZIZ.org/assets/docs/IMM-1218.pdf](#)).